Abstract Purpose: Preclinical studies have shown that the combination of topotecan and carboplatin is synergistic. To evaluate the schedule dependency of this interaction, the following phase I trial was designed to determine the safety and maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carboplatin and topotecan in patients with malignant solid tumors. Experimental Design: In part 1, patients received carboplatin on day 1and topotecan on days 1, 2, and 3 (C!Tschedule). In part 2, topotecan was administered on days 1, 2, and 3, followed by carboplatin on day 3 (T!C schedule). Pharmacokinetics were determined in plasma and DNA topoisomerase I catalytic activity and Pt-DNA adducts in WBC and tumor tissue. Results: Forty-one patients were included. Dose-limiting toxicities during the C!T schedule were grade 4 thrombocytopenia and febrile neutropenia (MTD: carboplatin target area under the free carboplatin plasma concentration versus time curve, 4 min mg/mL; topotecan, 0.5 mg/m 2 /d). Dose-limiting toxicities during the T!C schedule included grade 4 neutropenia, thrombocytopenia, neutropenic fever, and grade 4 nausea and vomiting (MTD: carboplatin target area under the free carboplatin plasma concentration versus time curve, 6 min mg/mL; topotecan, 0.9 mg/m 2 /d). One complete response and five partial responses were observed. The clearance of and exposure to carboplatin and topotecan did not depend on the sequence of drug administration. No schedule-dependent effects were seen in Pt-DNA levels and DNA topoisomerase I catalytic activity in WBC and tumor tissue. However, myelotoxicity was clearly more evident in the C!Tschedule. Conclusion: TheT!C schedule was better tolerated because both hematologic and nonhematologic toxicities were milder. Other pharmacodynamic factors than the ones investigated must explain the schedule-dependent differences in toxicities.
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Topotecan and carboplatin are both active anticancer drugs with an established use in the clinic. Topotecan, a water-soluble semisynthetic analogue of camptothecin, is licensed for the treatment of small-cell lung cancer, cervical cancer, and metastatic ovarian carcinoma (1 -4) . Carboplatin is an analogue of cisplatin, but with a milder nonhematologic toxicity profile and a broad spectrum of antitumor activity (5, 6) . Topotecan undergoes pH-dependent reversible hydrolysis from the active lactone form into the carboxylate form and vice versa (7, 8) . Topotecan inhibits DNA topoisomerase I (TopI) by binding to the cleavable complex (consisting of TopI covalently bound to DNA). The stabilized cleavable complex results in irreversible DNA double-strand breaks leading to cell death (9 -11) . The antineoplastic effect of carboplatin involves the formation of a covalent interaction with DNA, after which several Pt-DNA adducts are formed, ultimately leading to cell death. Approximately 90% of an administered dose of carboplatin is eliminated by glomerular filtration (12) . This makes it possible to individualize the dose of carboplatin based on renal function as estimated by creatinine clearance (13, 14) . The rationale for combining carboplatin and topotecan is the synergistic cytotoxicity observed between platinum agents and topoisomerase I inhibitors in preclinical models (15 -18) . To explain this synergism, a mechanistic model has been established, in which the TopI enzyme directly binds to the Pt-DNA adduct. Subsequently, topotecan binds to this complex, which yields large stabilized lesions to the DNA that are difficult to repair (17, 18) . Preclinical studies have shown that the sequence of cisplatin or carboplatin followed by topotecan was the most active sequence (17, 18) . This is in agreement with results from clinical studies: Increased hematologic toxicity was observed when cisplatin or carboplatin was given before topotecan compared with the reversed schedule (19 -24) . To evaluate the schedule dependency of this interaction, the following phase I trial was designed to determine the safety and maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carboplatin and topotecan in patients with advanced solid malignancies.
Patients and Methods
Eligibility. Patients were eligible if they had a histologically or cytologically confirmed solid tumor and a metastatic tumor accessible for biopsy. Other eligibility criteria included age z18 y, WHO performance status V2, and an estimated life expectancy z3 mo. Previous chemotherapy had to be discontinued for at least 4 wk before entry into the study or 6 wk in the case of mitomycin C or nitrosourea. Patients had to have acceptable hematologic blood values (WBC z3.5 Â 10 9 /L, absolute neutrophil count z1.5 Â 10 9 /L, platelets z100 Â 10 9 /L, hemoglobin level z9.0 g/dL), as well as acceptable renal and hepatic functions [creatinine clearance z60 mL/min, serum bilirubin V1.5 times the normal upper limit, and aspartate aminotransferase and alanine aminotransferase V2 times the normal upper limit (or V5 times the normal upper limit in the presence of hepatic metastases)]. The study protocol was approved by the Medical Ethics Committee of the hospital and all patients had to give written informed consent.
Treatment plan and study design. In the first part of the study, patients received carboplatin as a 60-min i.v. infusion on day 1 and topotecan as a 30-min i.v. infusion on day 1 (after carboplatin administration) and days 2 and 3 (C!T schedule). Carboplatin dosage was calculated using the target area under the free carboplatin plasma concentration versus time curve (AUC; in min mg/mL). For carboplatin, it has been shown in several studies that the clearance is linearly related to the glomerular filtration rate and, therefore, the AUC is also related to the glomerular filtration rate (25) . We calculated the carboplatin dose using the Calvert formula (13), with glomerular filtration rate estimated using the formula of Cockroft and Gault (26) . The starting dose (topotecan, 0.5 mg/m 2 /d; carboplatin target AUC, 4 min mg/mL) was based on the experience in other clinical trials (22, 23) . At least three patients were entered at each dose level. The MTD was defined as the highest dose level not producing dose-limiting toxicities (DLT) during the first treatment cycle in more than two of six patients. The sequence of drug administration was reversed in the second part of the study (T!C schedule): topotecan administered at days 1, 2, and 3, followed by carboplatin at day 3 (carboplatin administered after administration of topotecan on day 3). Dose escalation during the T!C schedule was started at the established MTD of the C!T schedule. Subsequently, the dose was further escalated according to the original plan. Treatment cycles in both parts of the study were repeated every 28 d.
Drug product. Topotecan (Hycamtin) was provided by GlaxoSmithKline Beecham Pharmaceuticals. Each vial contained topotecan as lyophilized cake that was equivalent to 4 mg of the free base. To prepare the drug for i.v. infusion, the lyophilized formulation was reconstituted with 4 mL of sterile water for injection before dilution in 0.9% NaCl. Carboplatin, supplied by Pharmachemie B.V., was prepared according to the local procedure.
Patient evaluation and follow-up. Pretreatment evaluation included a complete medical history and physical examination. Before and during every cycle, the following was assessed at defined time points: vital signs (days 1-3), physical examination including ECG (day 1), urinalysis (day 1), and laboratory assessments (chemistry on days 1 and 15, and complete blood cell counts on days 1, 8, 15, and 21). Tumor measurements were done at baseline and every other cycle and were evaluated according to the WHO criteria (27) . All toxicities were graded according to the National Cancer Institute Common Toxicity Criteria version 2.0 (28). DLTs were defined as any of the following events occurring during the first treatment cycle and related to study treatment: (a) grade 4 neutropenia lasting z7 days or associated with fever/infection; (b) grade 4 thrombocytopenia or requiring platelet
Translational Relevance
This study was designed to explore the mechanistic background of the synergistic interaction between topotecan and carboplatin, two active anticancer agents that are registered for the treatment of various malignancies. This study not only established the maximum tolerated doses of both the carboplatin!topotecan and the reversed schedule but also explored the pharmacokinetics and pharmacodynamics of both schedules.The schedule-dependent toxicity (the carboplatin!topotecan schedule seems to be far more toxic than the reversed schedule) could not be explained by the pharmacokinetic data obtained in this study. In addition, the measured pharmacodynamic parameters (in surrogate and in tumor tissue) provide no definite explanation for the schedule dependency. Still, this study provides important data on the pharmacodynamics of both studied agents. For instance, this is the first study addressing the relationship between Pt-DNA adduct levels in WBC and tumor tissue following administration of carboplatin. Pharmacokinetic studies. To determine the pharmacokinetics of topotecan, blood sampling was done during the C!T schedule on day 1 and during the T!C schedule on day 3 (day of carboplatin infusion). Samples were taken pre-dose and at 30 min, 1, 1.5, 2, 3, 4, 8, and 12 h after start of the infusion. Limited blood sampling for the determination of topotecan pharmacokinetics, according to a method that was previously established (29) , was done during the C!T schedule on day 2 and 3 during cycle 1 and at day 1 during cycle 2. During the T!C schedule, blood samples were taken during cycle 1 at days 1 and 2 and during cycle 2 at day 3. Samples were taken before infusion and at exactly 2.5 h after the start of the 30-min infusion. The levels of total topotecan (lactone + hydroxy acid) and topotecan lactone were determined using a validated high-performance liquid chromatography assay (29) . To describe carboplatin pharmacokinetics, sampling was done during the C!T schedule on day 1 of the first and second cycles. During the T!C schedule, sampling was done on day 3 of the first and second cycles. Blood samples were taken pre-dose and at 30 min, 1, 1.5, 2, 4, 7, and 24 h after start of the infusion during the first cycle of both schedules. During the second cycle, blood samples were taken pre-dose and at 1, 2, 4, 7, and 24 h after start of the infusion. For the determination of free platinum, plasma ultrafiltrate was prepared by adding 1 mL of plasma to the MPS-1 system equipped with 3-kDa YMT membranes (Amicon Division). Analysis was done using a validated Zeeman atomic absorption spectrometry method (30) .
Pharmacodynamic studies. A tumor biopsy was obtained from each patient during cycle 1, 24 h after the infusion of carboplatin. In the C!T schedule, the biopsy was taken on day 2, and in the T!C schedule, a tumor biopsy was taken on day 4. After collecting tumor tissue, samples were washed with 0.9% NaCl and subsequently divided into two aliquots and snap-frozen in liquid nitrogen. One aliquot was used for the determination of intrastrand platinum-DNA adducts (Pt-GG and Pt-AG) and TopI protein levels, and one aliquot was used to determine TopI catalytic activity. Pt-DNA adducts were quantified using a sensitive 32 P-postlabeling assay, which was validated in vitro and in vivo (31) . The TopI catalytic activity was assayed by relaxation of supercoiled pBR322 DNA as described previously (16) . The TopI catalytic activity was expressed as the lowest nuclear extract concentration (Ag protein/mL) at which the supercoiled DNA was completely relaxed. The TopI protein levels were determined by Western blotting using the human IGROV1 ovarian cell line as reference (32) . TopI levels were expressed relative to the TopI level present in 10 Ag of IGROV1 cell lysate. For the determination of Pt-DNA adducts in WBC, samples were taken during cycles 1 and 2, on day 1 during the C!T schedule, and on day 3 during the T!C schedule. Samples were taken before infusion and at 4 and 21 h after the start of the carboplatin infusion, and WBC fractions were isolated and purified as previously described (31) . For the determination of TopI catalytic activity in WBC, blood samples were collected in three CPT tm vacutainers (Becton Dickinson). Samples were taken during the C!T schedule on day 1 and during the T!C schedule on day 3 of the first and second cycles. Samples were taken before infusion, at the end of carboplatin infusion, and at the end of topotecan infusion. An additional sample was taken during both schedules directly after the tumor biopsy sample.
Pharmacokinetic and pharmacodynamic analyses. The pharmacokinetic parameters of topotecan and carboplatin during the first cycle on day 1 (C!T schedule) or day 3 (T!C schedule) were determined by noncompartmental analysis with WinNonLin software (version 4.1, Pharsight Corporation). The area under the concentration-time curve (AUC) and total plasma clearance of total topotecan, topotecan lactone, and free carboplatin were calculated. On the other days of topotecan administration, a limited sampling method was used to estimate topotecan clearance, which used one sample 2 h after the end of the Table 2 . Number of patients treated at each dose level Table 3 . Incidence of treatment-emergent hematologic toxicities for all cycles in patients treated with the combination of carboplatin and topotecan 41%/15% c 10%/3% 0%/0% 7%/2% 7%/3% 31%/8% 24%/6% 7%/2% 7%/7% 41%/13%
30-min infusion as previously described (33) . The area under the adduct curve (AUA; in fmol h/Ag DNA) of platinum-DNA adducts were calculated in WBC by the linear-logarithmic trapezoidal method up to the last measured data point without extrapolation (34) . Statistical analyses were done using the SPSS software package for Windows (version 11.0, SPSS, Inc.). Details about the statistical analyses can be found in Supplementary Data.
Results
Patient characteristics. Patient characteristics are shown in Table 1 ; the number of patients included at the different dose levels are summarized in Table 2 . Initially, three patients were included at dose level 1. No study-related DLT was observed. At dose level 2, three of six patients experienced a DLT. Subsequently, dose level 1 was expanded with another three patients and no DLTs were observed. Dose level 1 (carboplatin target AUC, 4 min mg/mL; topotecan, 0.5 mg/m 2 /d) was the MTD at the C!T schedule. During the T!C schedule, at dose level 2, one patient had to be replaced because the tumor biopsy failed. No DLTs were observed up to dose level 7. At this dose level, one patient experienced DLT and, subsequently, this cohort was expanded with another four patients. One extra patient was treated at dose level 7 due to ethical considerations because the patient was already informed about this study and very eager to participate when it seemed that all slots had been filled. Subsequently, one of these additional patients also experienced DLT. Although the number of patients with DLT at dose level 7 was two of seven, it was decided to reduce the dose to level 6. This decision was taken because five of seven patients experienced grade 3 to 4 thrombocytopenia during cycle one (two patients) or subsequent cycles. Thus, further dose escalation was expected to result in unmanageable thrombocytopenia. One DLT was observed (of six patients) at level 6, and therefore it was decided that dose level 6 (carboplatin target AUC, 6 min mg/mL; topotecan, 0.9 mg/m 2 /d) was safe at the T!C schedule. In total, 170 cycles were used for the 41 patients (median, 4; range, 1-12; Supplementary Table S1).
Adverse events. All patients were evaluable for toxicity. The treatment-related hematologic and nonhematologic toxicities are presented in Tables 3 and 4 Hematologic toxicity, primarily thrombocytopenia, was dose limiting for the combination of topotecan and carboplatin using the C!T schedule. At dose level 2 (C!T schedule), three of the six patients included developed DLT. Two patients had thrombocytopenia grade 4 and one patient had thrombocytopenia grade 4 combined with febrile neutropenia grade 4. Three patients in the C!T schedule had a dose reduction of both drugs due to severe hematologic toxicities after receiving 1, 1, and 3 cycles. In the T!C schedule, at level 7, two patients experienced DLT. The first patient had grade 4 neutropenia, thrombocytopenia, and neutropenic fever and also grade 3 nausea and grade 4 vomiting, despite prophylactic antiemetics. The second patient experienced grade 3 thrombocytopenia and was hospitalized because of epistaxis. At dose level 6, one of three extra patients experienced a DLT (grade 4 thrombocytopenia and neutropenic fever). Five patients in the T!C schedule had a dose reduction of both drugs and one patient of topotecan due to severe hematologic toxicities after receiving 3, 4, 4, 1, 1, and 1 cycle, respectively. From Table 3 , it can be concluded that the incidence of grade 3 to 4 hematologic toxicities and the number of cycles causing these toxicities were higher during the C!T schedule. Grade 3 to 4 thrombocytopenia was the main hematologic toxicity observed during both schedules, but the incidence during the C!T schedule (58% of all patients, 20% of all cycles) was higher compared with that during the T!C schedule (41% of all patients, 13% of all cycles). Nonhematologic toxicity was frequently observed but generally mild. Main toxicities were grade 1 to 2 fatigue, nausea, and vomiting. In general, the incidence of nonhematologic toxicities was lower during the T!C schedule compared with the C!T schedule, excluding grade 1 to 2 obstipation. Two patients treated at the T!C schedule experienced grade 3 nausea and grade 4 vomiting and went off-study after receiving 1 and 2 cycles, respectively.
Pharmacokinetics. Plasma samples for determining carboplatin, topotecan lactone, and topotecan total pharmacokinetics were obtained from 36, 32, and 37 patients, respectively. During the C!T and T!C schedules, the mean AUC of carboplatin was about 1 to 2 min mg/mL lower than the target AUC, as calculated by the method of Calvert with glomerular filtration rate estimated from the Cockroft and Gault formula (Supplementary Fig. S1 ; ref. 13 ). The AUC levels of unbound platinum, topotecan lactone, and total topotecan are shown in Table 5 . There were no significant differences in clearance of unbound platinum (P = 0.14; Table 6 ), topotecan lactone (P = 0.96; Table 7) , and total topotecan (P = 0.08; Table 7 ) between the two schedules. When comparing topotecan clearance during the C!T and T!C schedules between days 1, 2, and 3 of cycle 1 and day 1 or 3 of cycle 2, it was shown that the effect of day of treatment on total topotecan clearance was not significant (P = 0.67). There was also no significant effect of schedule on total topotecan clearance measured on different days (P = 0.54). Finally, there was no significant interaction between day of treatment and schedule on total topotecan clearance (P = 0.15).
Pharmacodynamics. The incidence of thrombocytopenia was related to carboplatin AUC and was more evident during the C!T schedule compared with the T!C schedule (Fig. 1A-C) . When comparing, at the same dose level, measured AUC of carboplatin or topotecan between the two schedules, the mean platelet decrease after all cycles was significantly higher during the C!T schedule (83.7% at the C!T and 59.3% at the T!C schedule, P = 0.0005). The decreases in absolute neutrophil count (78.3% at the C!T and 70.2% at the T!C schedule) and leucocytes (70.3% at the C!T and 57.0% at the T!C schedule) after all cycles were also more evident in the C!T schedule, although not statistically significant (P = 0.36 and P = 0.13, respectively). The results of the TopI catalytic activity in WBC during the C!T and T!C schedules are summarized in Supplementary Table S2A and B. Topotecan and carboplatin administration had a significant effect on TopI catalytic activity (P = 0.006). However, this effect was not schedule dependent (P = 0.32). Moreover, there was no significant interaction 7%/2% 3%/1% 7%/2% 24%/6% b 28%/7% Table 5 . Mean (SD) AUC levels of unbound platinum and topotecan during C!T and T!C schedules T !C 7 1.1 6 3.9 (0.7) k 31.7 (12.6) k 60.5 (28.4) c
between topotecan/carboplatin infusion and schedule on TopI catalytic activity (P = 0.15). We also found no significant correlation between TopI catalytic activity and TopI protein levels in tumor cells and there was no schedule dependency (R 2 = 0.04, P > 0.05; Supplementary Fig. S2 ). Pt-DNA adduct levels could be determined in 10 patients during cycle 1 of the C!T schedule and in 20 patients of the T!C schedule in WBC. During the C!T schedule, the AUA Pt-GG and Pt-AG values were in the range of 0.44 to 4.13 and 0.02 to 1.95 fmol h/Ag DNA, respectively. During the T!C schedule, the AUA values were in the range of 0.22 to 6.07 fmol h/Ag DNA for Pt-GG and 0.00 to 2.14 fmol h/Ag DNA for Pt-AG. Figure 2A and B presents a scatter plot of the AUA of Pt-GG as a function of the measured AUC of carboplatin. During both schedules, it was shown that there was a significant increase in AUA of Pt-GG in WBC when the measured AUC of carboplatin increased. When comparing the AUA Pt-GG values between the C!T and T!C schedules, no significant difference was found (P = 0.09). The AUA Pt-GG values were corrected for the measured AUC of carboplatin.
During the C!T schedule, Pt-GG and Pt-AG adduct levels in tumor tissue could be determined in 11 and 10 patients, respectively. The Pt-GG and Pt-AG levels were in the range of 0.20 to 0.96 and 0.01 to 0.21 fmol/Ag DNA, respectively. During the T!C schedule, Pt-GG and Pt-AG adduct levels in tumor tissue could be determined in 16 patients. The Pt-GG and Pt-AG levels were in the range of 0.62 to 1.81 and 0.11 to 0.33 fmol/Ag DNA, respectively. The Pt-GG levels in tumor tissue were compared with the Pt-GG levels in WBC that were taken at the time point of tumor biopsy. The results are depicted in Fig. 2C . No significant correlation was found between the Pt-GG adduct levels in WBC and tumor tissue during both schedules. The levels found in tumor tissue were significantly higher than those in WBC in the C!T schedule (P = 0.02) as well as in the T!C schedule (P = 0.0005). Figure 2D shows the relationship between tumor Pt-GG adduct levels and the measured AUC of carboplatin. No significant correlation was found. To investigate schedule dependency, the tumor Pt-GG adduct levels were corrected for the measured AUC. No significant difference was found between the C!T and T!C schedules (P = 0.14).
Response. Of the 41 patients, 39 had at least one postbaseline response evaluation (Supplementary Table S3 ). One patient (2%) with relapsed small-cell lung cancer had a confirmed complete response. Partial responses were documented in five patients (12%), two of which were treated at the C!T schedule (both ovarian cancer patients). The partial responses in the T!C schedule were observed in patients with ovarian cancer, small-cell lung cancer, and gastric cancer. In addition to these objective responses, 21 patients (51%) had stable disease varying between 1 and 8 months. Twelve patients (29%) had disease progression.
Discussion
In this trial, we examined the combination of carboplatin and topotecan in two different treatment schedules. The MTD for the C!T schedule was established at topotecan 0.5 mg/m 2 /d and carboplatin target AUC 4 min mg/mL, whereas dose escalation could be continued up to level 6 (topotecan 0.9 mg/m 2 /d and carboplatin AUC 6 min mg/mL) in the reversed schedule. These results are in agreement with other studies (24) . We individualized the dose of carboplatin using the Calvert formula and found a considerable variability between the target AUC and the measured AUC. This could be due to the Cockroft and Gault formula that was used to calculate the creatinine clearance. Previously, it has been shown that using this method results in underexposure to carboplatin (35) (36) (37) . Calculation of the creatinine clearance by a 51 Cr-EDTA measurement might have resulted in lower variability between the target and measured AUCs. However, the observed difference between the target and measured AUCs of carboplatin has, in our view, not affected the main outcome of the study.
The observed myelotoxicity was clearly different between the two schedules. This effect could not be attributed to a pharmacokinetic interaction because we found no significant difference in the clearance of carboplatin and topotecan between the C!T and T!C schedules. The observed schedule-dependent toxicity could also not be attributed to the here addressed pharmacodynamic factors. During both schedules, we found an increase in the concentration of nuclear extract needed for complete relaxation of supercoiled DNA, and the concentration of the nuclear extract needed for relaxation of DNA was highest when both agents were present. However, there was no schedule dependency. In addition, no correlation was found between TopI catalytic activity and TopI protein levels in tumor cells. It was expected that higher concentrations of TopI protein frequently found in tumor cells (38) were correlated with higher TopI catalytic activity, but this was not confirmed in our trial. The lack of correlation between TopI protein levels and TopI catalytic activity was also shown in other studies (39, 40) . During both schedules, we found a significant increase in AUA of Pt-GG in WBC when the measured AUC of carboplatin increased. However, when comparing the AUA Pt-GG values between the C!T and T!C schedules, no significant difference was found. This result Table 6 . Mean (SD) clearance of unbound platinum during C!T and T!C schedules is in accordance with the findings in vitro of the combination of topotecan and cisplatin, with no schedule-dependent effect found on the Pt-DNA adduct levels in WBC (17) . To our knowledge, this is the first report addressing the relationship between Pt-GG adduct levels in WBC and tumor tissue following treatment with carboplatin. Unfortunately, no correlations were found between the measured AUC of carboplatin and the Pt-GG adduct levels in tumor tissue and between the Pt-GG adduct levels in WBC and tumor tissue. The levels found in tumor tissue were significantly higher during both schedules compared with WBC. These results have also been recently reported for cisplatin (41) . The difference in Pt-GG adduct levels in tumor tissue compared with WBC could be due to differences in DNA repair mechanisms in tumor cells compared with WBC, differences in pH of tumor cells that can effect delivery (42), differences in scavenging thiol levels, or overexpression of multidrug resistance proteins MRP2 or the copper transporting P-type ATPase ATP7B (43, 44) . We hypothesize that pharmacodynamic factors other than the ones described here must explain the schedule-dependent differences in toxicities. In clinical studies, the most important pharmacodynamic parameter (the fixation of the cleavable complex by topotecan) cannot be measured. This is due to the rapid reversibility of the reaction and the lack of a sufficiently sensitive assay. It is plausible that the same pharmacodynamic interaction between carboplatin and topotecan takes place in myeloid precursor cells as identified in tumor cells in vitro. This synergy would explain the schedule-dependent myelotoxicity. Future studies are needed to determine any differential effect of carboplatin-topotecan in tumor versus myeloid cells. Although higher doses of topotecan and carboplatin could be administered in the T!C schedule, the results of the preclinical and our clinical studies indicate that the C!T schedule at a dose of topotecan 0.5 mg/m 2 /d and carboplatin target AUC 4 min mg/mL is preferred for further investigation. This schedule showed synergy with regard to toxicity (myelosuppression), and there may similarly be a positive antitumor synergy with lower doses of carboplatin and topotecan. Future studies randomizing the two schedules of carboplatin and topotecan are needed to unravel any difference in antitumor activity.
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